Fig. 3From: IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosisBirinapant treatment reduces RKO tumour cell migrative capacity. Upper panel: Migration ability of RKO cell lines treated with SMAC-mimetics AT-406 and Birinapant compared to the untreated cells. Cells were treated with AT-406 and Birinapant for 24 or 48 h and allowed to migrate. The values are the average of two independent experiments. Lower panel: Cell proliferation of cell line RKO co-treated with SMAC-mimetics AT-406 and Birinapant for 48 and 72 h. The values are the average of two independent experiments. Columns = number of cells/well (of 6-well plate)Back to article page